The Impact of Diet on the Gut-Microbiota-Brain Axis (NMB)

June 27, 2023 updated by: University College Cork

An Interventional Study on the Association Between Diet, Cognitive Function, Stress and the Gut Microbiota in Healthy Volunteers.

This study aims to investigate the effects of an 8-week dietary intervention on cognitive function, stress, and the gut microbiota in healthy adults with low fibre intake.

Study Overview

Detailed Description

The gut microbiota communicates bidirectionally with the brain via the microbiota-gut-brain axis to influence various aspects of human physiology, including host metabolism, immune function, behaviour, and cognition. Diet is a key modulator of the microbial composition, suggesting that the microbiota could explain the association between poor nutrition and decreasing health of the population. Dietary fibre is the main energy source for the gut microbiota and fundamentally impacts its composition and function. The microbiota-gut-brain axis has been proposed to mediate some of the effects of dietary fibre on the brain, for example through microbial metabolites (e.g., short-chain fatty acids (SCFA)), regulation of the immune system, and the microbial impact on gut hormones and neurotransmitters. Similarly, intake of fermented foods is positively associated with cognitive health and has been shown to alter the microbiota composition and function and exert an anti-inflammatory effect. However, no studies to date have examined the singular and combined effects of fermented and fibrous foods on the gut microbiota, cognition, and emotion. The present study aims to determine the role of diet on the microbiota-gut-brain axis and mental health.

Using a randomized-controlled, parallel, single-blinded design, participants consuming a habitually low fibre diet (N=200) will undergo an 8-week dietary intervention. Participants will receive one of four diets (n=50 in each group): high fibre (aim 24-35 grams/day), fermented foods (aim 4-6 portions/day), combined diet of fermented foods and high fibre (aim 25-30g/day of fibre and 3-4 servings/day of fermented foods) or control (dietary education according to national Irish guidelines). Cognitive, psychological, and biological measures will be compared at baseline and endpoint. During the intervention period, individuals will provide repeated faecal samples to assess temporal microbial changes.

Study Type

Interventional

Enrollment (Estimated)

200

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Elizabeth Schneider, PhD
  • Phone Number: (+353) 021 4901721
  • Email: eschneider@ucc.ie

Study Contact Backup

Study Locations

      • Cork, Ireland, T12YT20
        • Recruiting
        • APC Microbiome Ireland
        • Principal Investigator:
          • John F Cryan, PhD
        • Contact:
        • Sub-Investigator:
          • Gerard Clarke, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Be able to give written informed consent.
  • Be between 18 and 50 years of age.
  • Have a body mass index (BMI) between 18.5-29.9 Kg/m2.
  • Be in generally good health as determined by the investigator.

Exclusion Criteria:

  • Are less than 18 and greater than 50 years of age.
  • Have a BMI below 18.5 or above 29.9 Kg/m2.
  • Have a significant acute or chronic coexisting illness [cardiovascular, gastrointestinal (GI) [to include functional GI disorders, inflammatory bowel disease, coeliac disease, lactose intolerance, food allergies], immunological, psychiatric [to include formal or as determined by MINI Psychiatric interview, diagnosis of current major depression, anxiety disorder, bipolar spectrum disorder, schizophrenia, other DSM-IV Axis I disorder], neurodevelopmental disorders, immunological, metabolic disorders [to include type I or II diabetes], or any condition which contraindicates, in the investigators judgement, entry to the study,
  • Have a condition or taking a medication that the investigator believes would interfere with the objectives of the study, pose a safety risk, or confound the interpretation of the study results; all psychoactive medications [to include anxiolytics, antipsychotics, antidepressants, anticonvulsants, centrally acting corticosteroids, and opioid pain relievers), laxatives, enemas, antibiotics, anti-coagulants, over-the counter non-steroidal anti-inflammatories (NSAIDS). Subjects should have a wash-out period of 4 weeks.
  • Current prebiotic or probiotic supplement use (a wash-out period of 4 weeks after cessation will allow entry to the study).
  • Females who are peri-menopausal, menopausal or post-menopausal.
  • Females who are pregnant or planning a pregnancy, or lactating.
  • Participants who are not fluent in English.
  • Are colour blind.
  • Have dyslexia or dyscalculia.
  • Are a current habitual daily smoker.
  • Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the trial.
  • Subjects receiving treatment involving experimental drugs. If the subject has been in a recent experimental trial, these must have been completed not less than 30 days prior to this study.
  • Have a malignant disease or any concomitant end-stage organ disease.
  • Have completed a study in our laboratory in the past 4 years.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Factorial Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Control
Participants will recieve dietary education based on the healthy eating guidleines provided by the Health Service Executive (HSE).
Participants will recieve dietary education based on the Irish healthy food pyramid.
Experimental: Fermented Foods
Fermented foods diet (4-6 portions/day)
Participants will recieve dietary education to include 4 to 6 portions of fermented foods to their normal diet.
Experimental: High Fibre
High fibre diet (24-35 grams/day)
Participants will recieve dietary education to increase their fibre intake to 24-35g/day in their normal diet.
Experimental: Combined Diet
Combined diet high in fibre and fermented foods (fibre aim 24-35 grams/day, fermented foods aim 4-6 portions/day)
Participants will recieve dietary education to increase their fibre intake to 25-30g/day and include 3 to 4 portions of fermented foods to their normal diet.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Trait stress/mood: self-report
Time Frame: Change from baseline at 8 weeks
self-report questionnaires
Change from baseline at 8 weeks
Trait stress/mood: hypothalamic-pituitary-adrenal axis activity
Time Frame: Change from baseline at 8 weeks
Cortisol from saliva samples
Change from baseline at 8 weeks
Responses to acute stress: self-report
Time Frame: Change from baseline at 8 weeks
Self-report questionnaires
Change from baseline at 8 weeks
Responses to acute stress: sympathetic-adrenal-medullary pathway activity
Time Frame: Change from baseline at 8 weeks
Galvanic skin response taken from the skin on the hand
Change from baseline at 8 weeks
Responses to acute stress: hypothalamic-pituitary-adrenal axis activity
Time Frame: Change from baseline at 8 weeks
Cortisol from saliva samples
Change from baseline at 8 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cognitive performance: working memory
Time Frame: Change from baseline at 8 weeks
Spatial Working Memory
Change from baseline at 8 weeks
Cognitive performance: episodic memory
Time Frame: Change from baseline at 8 weeks
Modified Rey Auditory Verbal Learning Test (ModRey)
Change from baseline at 8 weeks
Cognitive performance: decision making
Time Frame: Change from baseline at 8 weeks
Iowa Gambling Task
Change from baseline at 8 weeks
Cognitive performance: emotional inhibition
Time Frame: Change from baseline at 8 weeks
Emotional Stroop
Change from baseline at 8 weeks
Cognitive performance: sustained attention
Time Frame: Change from baseline at 8 weeks
Rapid Visual Information Processing
Change from baseline at 8 weeks
Cognitive performance: visual pattern recognition memory
Time Frame: Change from baseline at 8 weeks
Pattern Recognition Memory
Change from baseline at 8 weeks
Cognitive performance: cognitive flexibility
Time Frame: Change from baseline at 8 weeks
Intra-Extra Dimensional Set Shifting
Change from baseline at 8 weeks
Cognitive performance: social cognition
Time Frame: Change from baseline at 8 weeks
Emotion Recognition Task
Change from baseline at 8 weeks
Cognitive performance: affective perceptual bias
Time Frame: Change from baseline at 8 weeks
Emotional Bias Task
Change from baseline at 8 weeks
Microbiota composition and function
Time Frame: Change from baseline at 8 weeks
Shotgun metagenomics of fecal samples
Change from baseline at 8 weeks
Microbial and host metabolomics
Time Frame: Change from baseline at 8 weeks
Untargeted metabolomics analysis
Change from baseline at 8 weeks
Inflammation
Time Frame: Change from baseline at 8 weeks
Inflammatory markers in lipopolysaccharide stimulated and unstimulated bloods
Change from baseline at 8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: John Cryan, PhD, APC Microbiome Ireland

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 14, 2022

Primary Completion (Estimated)

July 1, 2026

Study Completion (Estimated)

July 1, 2026

Study Registration Dates

First Submitted

June 12, 2023

First Submitted That Met QC Criteria

June 27, 2023

First Posted (Actual)

July 5, 2023

Study Record Updates

Last Update Posted (Actual)

July 5, 2023

Last Update Submitted That Met QC Criteria

June 27, 2023

Last Verified

June 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • APC 150b

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on Control

3
Subscribe